SciMar Ltd. is a private Manitoba company founded on the discovery of the mechanisim of pre-diabetic insulin resistance (AMIS Syndrome) and resultant pathologies including: Type 2 Diabetes, Obesity, Cardiovascular and renal disease, and blindness. Our mechanistic-targeted disease managment approach has led to the development of novel solutions for diagnostics, prevention, and treatment that will revolutionize this major market.